Here are the 10-K annual reports from Alector, Inc. (ALEC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALEC filings page.
Alector, Inc. files its Annual Report describing a clinical-stage neurology pipeline focused on genetically validated therapies for Alzheimer’s, Parkinson’s and related neurodegenerative diseases. The company uses targeted mechanisms to remove pathogenic proteins, replace deficient proteins and restore cellular function.
The lead asset, nivisnebart, a progranulin-elevating antibody partnered with GSK, has completed enrollment in a 76‑week Phase 2 PROGRESS‑AD trial in early Alzheimer’s disease, with an interim futility analysis planned for the first half of 2026. Alector also highlights wholly owned preclinical programs, including AL137 (anti‑amyloid beta), AL050 (GCase enzyme replacement) and ABC‑enabled siRNA candidates for tau, alpha‑synuclein and NLRP3.
The report emphasizes the proprietary Alector Brain Carrier (ABC) platform for blood‑brain barrier delivery across antibodies, enzymes and siRNA, and outlines an ongoing strategic alliance with GSK, which provided $700 million in upfront payments and up to $1.5 billion in potential milestones with U.S. profit‑sharing on key programs.